Scientists pinpoint driver of IBD and other disorders with work under way to adapt existing drugs to treat patients
      • Pronell@lemmy.world
        10·
        7 months ago

        Meh. I have mine mostly under control so if they price it out of reach, so be it.

        But given that the article says it’s reformulating existing drugs to work here, they may be considerably cheaper than expected.

  • AbouBenAdhem@lemmy.worldEnglish
    162·
    7 months ago

    The Fisher King to Perceval: “The real Holy Grail was the irritable bowel syndrome we acquired along the way.”

  • bean@lemmy.world
    9·
    7 months ago

    Researchers have discovered a key biological pathway that drives inflammatory bowel disease (IBD) and other autoimmune disorders. This breakthrough centers on a gene called ETS2 that regulates the inflammatory behavior of immune cells called macrophages. The same pathway is thought to underlie conditions like ankylosing spondylitis and autoimmune liver and artery diseases. Existing cancer drugs called MEK inhibitors can dampen the activity of ETS2, suggesting a potential treatment approach. The researchers are now working to develop a targeted version of these drugs to treat IBD and related conditions, with clinical trials expected within 5 years. This discovery represents a major advance in understanding the fundamental causes of IBD and other immune disorders.

    Kagi Summarized